|

REGN7075 Clinical Trials

3 actively recruiting trials across 3 locations

No change since June 2026

Also known as: EGFRxCD28 bispecific immunotherapy, marlotamig

Pipeline

Phase 2: 3

Top Sponsors

  • Regeneron Pharmaceuticals2
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

Indications

  • Cancer3
  • Lung Cancer2
  • Advanced/Metastatic Non-Small Cell Lung Cancer1
  • Colorectal Cancer1
  • Non Small Cell Lung Cancer1

Goodyear, Arizona1 trial

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Cancer Treatment Centers of America, Phoenix

Phase 2

Orange, California1 trial

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

University of California Irvine

Phase 2

Baltimore, Maryland1 trial

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.